Cargando…

Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)

AIMS: Low C-peptide levels, indicating beta-cell dysfunction, are associated with increased within-day glucose variation and hypoglycemia. In advanced type 2 diabetes, severe hypoglycemia and increased glucose variation predict cardiovascular (CVD) risk. The present study examined the association be...

Descripción completa

Detalles Bibliográficos
Autores principales: Koska, Juraj, Nuyujukian, Daniel S., Bahn, Gideon D., Zhou, Jin J., Reaven, Peter D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656002/
https://www.ncbi.nlm.nih.gov/pubmed/34879878
http://dx.doi.org/10.1186/s12933-021-01418-z
_version_ 1784612193582448640
author Koska, Juraj
Nuyujukian, Daniel S.
Bahn, Gideon D.
Zhou, Jin J.
Reaven, Peter D.
author_facet Koska, Juraj
Nuyujukian, Daniel S.
Bahn, Gideon D.
Zhou, Jin J.
Reaven, Peter D.
author_sort Koska, Juraj
collection PubMed
description AIMS: Low C-peptide levels, indicating beta-cell dysfunction, are associated with increased within-day glucose variation and hypoglycemia. In advanced type 2 diabetes, severe hypoglycemia and increased glucose variation predict cardiovascular (CVD) risk. The present study examined the association between C-peptide levels and CVD risk and whether it can be explained by visit-to-visit glucose variation and severe hypoglycemia. MATERIALS AND METHODS: Fasting C-peptide levels at baseline, composite CVD outcome, severe hypoglycemia, and visit-to-visit fasting glucose coefficient of variation (CV) and average real variability (ARV) were assessed in 1565 Veterans Affairs Diabetes Trial participants. RESULTS: There was a U-shaped relationship between C-peptide and CVD risk with increased risk with declining levels in the low range (< 0.50 nmol/l, HR 1.30 [95%CI 1.05–1.60], p = 0.02) and with rising levels in the high range (> 1.23 nmol/l, 1.27 [1.00–1.63], p = 0.05). C-peptide levels were inversely associated with the risk of severe hypoglycemia (OR 0.68 [0.60–0.77]) and visit-to-visit glucose variation (CV, standardized beta-estimate − 0.12 [SE 0.01]; ARV, − 0.10 [0.01]) (p < 0.0001 all). The association of low C-peptide levels with CVD risk was independent of cardiometabolic risk factors (1.48 [1.17–1.87, p = 0.001) and remained associated with CVD when tested in the same model with severe hypoglycemia and glucose CV. CONCLUSIONS: Low C-peptide levels were associated with increased CVD risk in advanced type 2 diabetes. The association was independent of increases in glucose variation or severe hypoglycemia. C-peptide levels may predict future glucose control patterns and CVD risk, and identify phenotypes influencing clinical decision making in advanced type 2 diabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01418-z.
format Online
Article
Text
id pubmed-8656002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86560022021-12-10 Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT) Koska, Juraj Nuyujukian, Daniel S. Bahn, Gideon D. Zhou, Jin J. Reaven, Peter D. Cardiovasc Diabetol Original Investigation AIMS: Low C-peptide levels, indicating beta-cell dysfunction, are associated with increased within-day glucose variation and hypoglycemia. In advanced type 2 diabetes, severe hypoglycemia and increased glucose variation predict cardiovascular (CVD) risk. The present study examined the association between C-peptide levels and CVD risk and whether it can be explained by visit-to-visit glucose variation and severe hypoglycemia. MATERIALS AND METHODS: Fasting C-peptide levels at baseline, composite CVD outcome, severe hypoglycemia, and visit-to-visit fasting glucose coefficient of variation (CV) and average real variability (ARV) were assessed in 1565 Veterans Affairs Diabetes Trial participants. RESULTS: There was a U-shaped relationship between C-peptide and CVD risk with increased risk with declining levels in the low range (< 0.50 nmol/l, HR 1.30 [95%CI 1.05–1.60], p = 0.02) and with rising levels in the high range (> 1.23 nmol/l, 1.27 [1.00–1.63], p = 0.05). C-peptide levels were inversely associated with the risk of severe hypoglycemia (OR 0.68 [0.60–0.77]) and visit-to-visit glucose variation (CV, standardized beta-estimate − 0.12 [SE 0.01]; ARV, − 0.10 [0.01]) (p < 0.0001 all). The association of low C-peptide levels with CVD risk was independent of cardiometabolic risk factors (1.48 [1.17–1.87, p = 0.001) and remained associated with CVD when tested in the same model with severe hypoglycemia and glucose CV. CONCLUSIONS: Low C-peptide levels were associated with increased CVD risk in advanced type 2 diabetes. The association was independent of increases in glucose variation or severe hypoglycemia. C-peptide levels may predict future glucose control patterns and CVD risk, and identify phenotypes influencing clinical decision making in advanced type 2 diabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01418-z. BioMed Central 2021-12-08 /pmc/articles/PMC8656002/ /pubmed/34879878 http://dx.doi.org/10.1186/s12933-021-01418-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Koska, Juraj
Nuyujukian, Daniel S.
Bahn, Gideon D.
Zhou, Jin J.
Reaven, Peter D.
Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
title Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
title_full Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
title_fullStr Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
title_full_unstemmed Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
title_short Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
title_sort association of low fasting c-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the veterans affairs diabetes trial (vadt)
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656002/
https://www.ncbi.nlm.nih.gov/pubmed/34879878
http://dx.doi.org/10.1186/s12933-021-01418-z
work_keys_str_mv AT koskajuraj associationoflowfastingcpeptidelevelswithcardiovascularriskvisittovisitglucosevariationandseverehypoglycemiaintheveteransaffairsdiabetestrialvadt
AT nuyujukiandaniels associationoflowfastingcpeptidelevelswithcardiovascularriskvisittovisitglucosevariationandseverehypoglycemiaintheveteransaffairsdiabetestrialvadt
AT bahngideond associationoflowfastingcpeptidelevelswithcardiovascularriskvisittovisitglucosevariationandseverehypoglycemiaintheveteransaffairsdiabetestrialvadt
AT zhoujinj associationoflowfastingcpeptidelevelswithcardiovascularriskvisittovisitglucosevariationandseverehypoglycemiaintheveteransaffairsdiabetestrialvadt
AT reavenpeterd associationoflowfastingcpeptidelevelswithcardiovascularriskvisittovisitglucosevariationandseverehypoglycemiaintheveteransaffairsdiabetestrialvadt